Evidence map›Paper›PMID 27611194›Full record

ArticlePloS one2016

The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.

Nancy A Stearns, Shuxia Zhou, Michelle Petri, Steven R Binder, David S Pisetsky

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. An immunoassay based on polyHRP signal amplification for HPV16/18 E6 RNA detection with anti-DNA-RNA hybrid antibody.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Article
  3. Article
  4. A Blood Test for the Diagnosis of Multiple Sclerosis.International journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies.Biologicals : journal of the International Association of Biological Standardization · 2020
    Article
  11. The binding of SLE autoantibodies to mitochondria.Clinical immunology (Orlando, Fla.) · 2020
    Article
  12. Antinuclear Antibodies in Systemic Sclerosis: an Update.Clinical reviews in allergy & immunology · 2020
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Nancy A StearnsDivision of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Shuxia ZhouBio-Rad Laboratories Clinical Diagnostic Group, 400 Alfred Nobel Drive, Hercules, California, United States of America.
Michelle PetriDivision of Rheumatology, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, Maryland, United States of America.
Steven R BinderBio-Rad Laboratories Clinical Diagnostic Group, 400 Alfred Nobel Drive, Hercules, California, United States of America.
David S PisetskyDivision of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Bio-Rad (United States) · USDuke Medical Center · USDurham VA Medical Center · USJohns Hopkins Medicine · US

Funding

Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
NIAMS NIH HHS R01 AR043727
6 · The paper itself

Abstract

Antibodies to nuclear antigens (antinuclear antibodies or ANAs) are the serological hallmark of systemic lupus erythematosus (SLE). These antibodies bind diverse nuclear antigens that include DNA, histones and non-histone proteins as well as complexes of proteins with DNA and RNA. Because of the frequency of ANA expression in SLE, testing is an important component of clinical evaluation as well as determination of eligibility for clinical trials or utilization of certain therapies. Immunofluorescence assays have been commonly used for this purpose although this approach can be limited by issues of throughput, variability and difficulty in determining positivity. ELISA and multiplex assays are also useful approaches although these assays may give an incomplete picture of antibodies present. To develop a sensitive and quantitative ANA assay, we have explored an ELISA platform in which plates are pre-coated with a positively charged nucleic acid binding polymer (NABP) to increase adherence of antigens containing DNA or RNA. As a source of antigens, we have used supernatants of Jurkat cells undergoing apoptosis in vitro. As results presented show, a poly-L-lysine (PLL) pre-coat significantly enhances detection of antibodies to DNA as well as antigens such as histones, SSA, SSB and RNP. Comparison of the ELISA assay with the PLL pre-coat with a multiplex assay using the BioPlex® 2200 system indicated good agreement in results for a panel of lupus sera. Together, these studies indicate that a pre-coat with a positively charged polymer can increase the sensitivity of an ANA ELISA using as antigens molecules released from dead and dying cells. This assay platform may facilitate ANA testing by providing an ensemble of antigens more similar in composition and structure with antigens present in vivo, with a NABP promoting adherence via charge-charge interactions.

Indexed as

Enzyme-Linked Immunosorbent AssayAntibodies, AntinuclearApoptosisDeoxyribonuclease IDNAHumansJurkat CellsNucleosomesPolylysineAntibodies, AntinuclearDeoxyribonuclease IDNANucleosomesPolylysine

Identifiers

PMID27611194
PMCPMC5017613
OpenAlexW2515193610

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.